Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
+44 1478 350008
ISSN: 2329-8790
+44 1478 350008
Edward Peres
Henry Ford Hospital, USA
Posters & Accepted Abstracts: J Hematol Thrombo Dis
Background: Myelodysplastic syndrome with concomitant bone marrow fibrosis is associated with a dismal prognosis with conventional therapy. Allogeneic stem cell transplant has been utilized in young fit patients with this disorder. However, the data on the outcomes of an older patient population is unknown. Design & Methods: Patients with myelodysplastic syndrome with known bone marrow histology (n=11) who underwent hematopoietic stem cell transplantation at our center were reviewed and classified according to the degree of bone marrow fibrosis and analyzed regarding cytogenetic abnormality, Jak2, engraftment, treatment-related mortality, relapse and overall survival. Results: The cytogenetic abnormality, age, degree of bone marrow fibrosis and conditioning regimen was not associated with inferior survival in invariant analysis. The total frequency of engraftment accomplished at day +30 neutrophil and the middle time to platelet engraftment. The combined occurrence of backslide at 3 years was bringing about practically identical 3-year sickness free survival rates in. There were no patients who developed graft failure after HSCT. Conclusions: Among patients with myelodysplastic syndromes and concomitant bone marrow fibrosis, even with advanced age, higher grade of marrow fibrosis or cytogenetic abnormality did not affect overall survival after hematopoietic stem cell transplantation. This therapeutic modality should be considered in patients even with advanced age and significant fibrosis.
Email: eperes1@hfhs.org